It is anticipated that the market held a valuation of USD 5,800 million in 2018 and is projected to register a CAGR of around 9.80% over the forecast period.

Blood illnesses that affect red blood cells are known as hemoglobinopathies. These illnesses can be hereditary, resulting in an aberrant structure of one of the globin chains in the haemoglobin molecule.